BLCO
BLCO
Bausch + Lomb CorporationIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.24B ▼ | $645M ▼ | $-71M ▼ | -5.71% ▼ | $-0.2 ▼ | $160M ▼ |
| Q4-2025 | $1.41B ▲ | $658M ▲ | $-58M ▼ | -4.13% ▼ | $-0.16 ▼ | $257M ▲ |
| Q3-2025 | $1.28B ▲ | $623M ▼ | $-28M ▲ | -2.19% ▲ | $-0.08 ▲ | $189M ▲ |
| Q2-2025 | $1.28B ▲ | $675M ▲ | $-62M ▲ | -4.85% ▲ | $-0.18 ▲ | $118M ▲ |
| Q1-2025 | $1.14B | $649M | $-212M | -18.65% | $-0.6 | $45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $268M ▼ | $13.78B ▼ | $7.33B ▼ | $6.38B ▼ |
| Q4-2025 | $383M ▲ | $14.02B ▲ | $7.5B ▲ | $6.45B ▲ |
| Q3-2025 | $310M ▲ | $13.83B | $7.33B ▲ | $6.43B ▼ |
| Q2-2025 | $272M ▲ | $13.83B ▲ | $7.32B ▲ | $6.44B ▲ |
| Q1-2025 | $202M | $13.43B | $7B | $6.36B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-71M ▼ | $32M ▼ | $-130M ▲ | $-20M ▼ | $-118M ▼ | $-68M ▼ |
| Q4-2025 | $-58M ▼ | $134.34M ▼ | $-184.86M ▼ | $114.8M ▲ | $65M ▲ | $61.8M ▼ |
| Q3-2025 | $-28M ▲ | $139.05M ▲ | $-61.3M ▲ | $-12.55M ▼ | $60M ▲ | $64.53M ▲ |
| Q2-2025 | $-58M ▲ | $35M ▲ | $-90M ▲ | $90M ▲ | $57M ▲ | $-54M ▲ |
| Q1-2025 | $-211M | $-25M | $-116M | $31M | $-101M | $-135M |
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
Branded and Other Generic Products | $60.00M ▲ | $60.00M ▲ | $70.00M ▲ | $50.00M ▼ |
Device Products | $470.00M ▲ | $480.00M ▲ | $520.00M ▲ | $480.00M ▼ |
Other Revenues | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $10.00M ▲ |
Over the Counter Products | $480.00M ▲ | $450.00M ▼ | $490.00M ▲ | $440.00M ▼ |
Pharmaceutical Products | $260.00M ▲ | $280.00M ▲ | $320.00M ▲ | $270.00M ▼ |
Revenue by Geography
| Region | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
CANADA | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ |
CHINA | $80.00M ▲ | $90.00M ▲ | $90.00M ▲ | $100.00M ▲ |
FRANCE | $60.00M ▲ | $60.00M ▲ | $50.00M ▼ | $50.00M ▲ |
GERMANY | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $30.00M ▼ |
ITALY | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
JAPAN | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $50.00M ▲ |
KOREA REPUBLIC OF | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
MEXICO | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
Other Countries | $170.00M ▲ | $170.00M ▲ | $170.00M ▲ | $240.00M ▲ |
POLAND | $10.00M ▲ | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ |
SPAIN | $20.00M ▲ | $30.00M ▲ | $20.00M ▼ | $30.00M ▲ |
United States and Puerto Rico | $540.00M ▲ | $610.00M ▲ | $610.00M ▲ | $660.00M ▲ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Bausch + Lomb Corporation's financial evolution and strategic trajectory over the past five years.
BLCO combines a globally recognized brand, a broad and integrated portfolio across key eye care segments, and a revitalized innovation pipeline. Revenue growth has been solid and accelerating, supported by differentiated technologies in contact lenses and surgical products and by strategic moves in dry eye and other therapeutic areas. The balance sheet now shows low debt and a net cash position, giving the company more flexibility to weather volatility and continue funding its strategic initiatives. Its long history and deep relationships with eye care professionals provide an intangible advantage that is difficult for newer entrants to replicate.
The main risks are financial and competitive. Profitability has deteriorated from modest profits to persistent losses, with negative net margins, shrinking EBITDA, and weak or negative free cash flow over several recent years. Rising operating expenses, investment needs, and prior interest costs have weighed heavily on results, leading to negative retained earnings and a thinner equity cushion. The asset base is heavily skewed toward goodwill and intangibles, which could be vulnerable if business performance does not meet expectations. On top of this, BLCO faces intense competition in every major product category, and its reliance on a limited number of key products creates concentration risk.
Looking ahead, BLCO’s prospects hinge on its ability to translate strong revenue momentum and a promising innovation pipeline into sustainable profits and healthier cash flows. The recent deleveraging and solid liquidity put the company in a better position to execute its strategy without the same financial strain as before. If management can improve cost discipline, enhance operating efficiency, and successfully launch and scale upcoming products in contact lenses, dry eye, and myopia control, the long-term opportunity in global eye care is substantial. However, until profitability and free cash flow show consistent and durable improvement, the story will remain a balance between an attractive strategic position and meaningful execution and financial risks.
About Bausch + Lomb Corporation
https://www.bausch.comBausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.24B ▼ | $645M ▼ | $-71M ▼ | -5.71% ▼ | $-0.2 ▼ | $160M ▼ |
| Q4-2025 | $1.41B ▲ | $658M ▲ | $-58M ▼ | -4.13% ▼ | $-0.16 ▼ | $257M ▲ |
| Q3-2025 | $1.28B ▲ | $623M ▼ | $-28M ▲ | -2.19% ▲ | $-0.08 ▲ | $189M ▲ |
| Q2-2025 | $1.28B ▲ | $675M ▲ | $-62M ▲ | -4.85% ▲ | $-0.18 ▲ | $118M ▲ |
| Q1-2025 | $1.14B | $649M | $-212M | -18.65% | $-0.6 | $45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $268M ▼ | $13.78B ▼ | $7.33B ▼ | $6.38B ▼ |
| Q4-2025 | $383M ▲ | $14.02B ▲ | $7.5B ▲ | $6.45B ▲ |
| Q3-2025 | $310M ▲ | $13.83B | $7.33B ▲ | $6.43B ▼ |
| Q2-2025 | $272M ▲ | $13.83B ▲ | $7.32B ▲ | $6.44B ▲ |
| Q1-2025 | $202M | $13.43B | $7B | $6.36B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-71M ▼ | $32M ▼ | $-130M ▲ | $-20M ▼ | $-118M ▼ | $-68M ▼ |
| Q4-2025 | $-58M ▼ | $134.34M ▼ | $-184.86M ▼ | $114.8M ▲ | $65M ▲ | $61.8M ▼ |
| Q3-2025 | $-28M ▲ | $139.05M ▲ | $-61.3M ▲ | $-12.55M ▼ | $60M ▲ | $64.53M ▲ |
| Q2-2025 | $-58M ▲ | $35M ▲ | $-90M ▲ | $90M ▲ | $57M ▲ | $-54M ▲ |
| Q1-2025 | $-211M | $-25M | $-116M | $31M | $-101M | $-135M |
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
Branded and Other Generic Products | $60.00M ▲ | $60.00M ▲ | $70.00M ▲ | $50.00M ▼ |
Device Products | $470.00M ▲ | $480.00M ▲ | $520.00M ▲ | $480.00M ▼ |
Other Revenues | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $10.00M ▲ |
Over the Counter Products | $480.00M ▲ | $450.00M ▼ | $490.00M ▲ | $440.00M ▼ |
Pharmaceutical Products | $260.00M ▲ | $280.00M ▲ | $320.00M ▲ | $270.00M ▼ |
Revenue by Geography
| Region | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
CANADA | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ |
CHINA | $80.00M ▲ | $90.00M ▲ | $90.00M ▲ | $100.00M ▲ |
FRANCE | $60.00M ▲ | $60.00M ▲ | $50.00M ▼ | $50.00M ▲ |
GERMANY | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $30.00M ▼ |
ITALY | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
JAPAN | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $50.00M ▲ |
KOREA REPUBLIC OF | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
MEXICO | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
Other Countries | $170.00M ▲ | $170.00M ▲ | $170.00M ▲ | $240.00M ▲ |
POLAND | $10.00M ▲ | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ |
SPAIN | $20.00M ▲ | $30.00M ▲ | $20.00M ▼ | $30.00M ▲ |
United States and Puerto Rico | $540.00M ▲ | $610.00M ▲ | $610.00M ▲ | $660.00M ▲ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Bausch + Lomb Corporation's financial evolution and strategic trajectory over the past five years.
BLCO combines a globally recognized brand, a broad and integrated portfolio across key eye care segments, and a revitalized innovation pipeline. Revenue growth has been solid and accelerating, supported by differentiated technologies in contact lenses and surgical products and by strategic moves in dry eye and other therapeutic areas. The balance sheet now shows low debt and a net cash position, giving the company more flexibility to weather volatility and continue funding its strategic initiatives. Its long history and deep relationships with eye care professionals provide an intangible advantage that is difficult for newer entrants to replicate.
The main risks are financial and competitive. Profitability has deteriorated from modest profits to persistent losses, with negative net margins, shrinking EBITDA, and weak or negative free cash flow over several recent years. Rising operating expenses, investment needs, and prior interest costs have weighed heavily on results, leading to negative retained earnings and a thinner equity cushion. The asset base is heavily skewed toward goodwill and intangibles, which could be vulnerable if business performance does not meet expectations. On top of this, BLCO faces intense competition in every major product category, and its reliance on a limited number of key products creates concentration risk.
Looking ahead, BLCO’s prospects hinge on its ability to translate strong revenue momentum and a promising innovation pipeline into sustainable profits and healthier cash flows. The recent deleveraging and solid liquidity put the company in a better position to execute its strategy without the same financial strain as before. If management can improve cost discipline, enhance operating efficiency, and successfully launch and scale upcoming products in contact lenses, dry eye, and myopia control, the long-term opportunity in global eye care is substantial. However, until profitability and free cash flow show consistent and durable improvement, the story will remain a balance between an attractive strategic position and meaningful execution and financial risks.

CEO
Brenton L. Saunders
Compensation Summary
(Year )
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Evercore ISI Group
In Line
HC Wainwright & Co.
Buy
Citigroup
Buy
Barclays
Equal Weight
Wells Fargo
Equal Weight
Stifel
Hold
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
DEUTSCHE BANK AG\
Shares:3.53M
Value:$55.22M
ICAHN CARL C
Shares:3.5M
Value:$54.77M
OAKTREE CAPITAL MANAGEMENT LP
Shares:3.38M
Value:$52.94M
Summary
Showing Top 3 of 134

